Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [18F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4391-4402

  Via, Laura E ^a   Schimel, Dan ^a   Weiner, Danielle M ^a   Dartois, Veronique ^b   Dayao, Emmanuel ^a   Cai, Ying ^a   Yoon, Young Soon ^a   Dreher, Matthew R ^c   Kastenmayer, Robin J ^a   Laymon, Charles M ^d   Carny, J Eoin ^d   Flynn, JoAnne L ^e   Herscovitch, Peter ^c   Barry III, Clifton E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ISONIAZID; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COURSE EVALUATION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; EXPERIMENTAL RABBIT; FEMALE; HISTOPATHOLOGY; IMAGE ANALYSIS; LUNG GRANULOMATOSIS; LUNG SCINTISCANNING; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; GRANULOMA; ISONIAZID; LUNG; MYCOBACTERIUM TUBERCULOSIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RABBITS; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84864386253     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00531-12     Document Type: Article

References (54)

1. Andreu J, Caceres J, Pallisa E, Martinez-Rodriguez M. 2004. Radiological manifestations of pulmonary tuberculosis. Eur. J. Radiol. 51:139-149. (Pubitemid 38916615)
2. Basaraba RJ. 2008. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb.) 88(Suppl. 1):S35-S47.
3. Benz MR, et al. 2008. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J. Nucl. Med. 49:1579-1584.
4. Berry MP, et al. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466:973-977.
5. Bishai WR, et al. 1999. Virulence of Mycobacterium tuberculosis CDC1551 and H37Rv in rabbits evaluated by Lurie's pulmonary tubercle count method. Infect. Immun. 67:4931-4934. (Pubitemid 29400486)
6. Capuano SV, III, et al. 2003. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71:5831-5844.
7. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. 2004. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am. J. Respir. Crit. Care Med. 170:1124-1130. (Pubitemid 39488627)
8. Chegou NN, Walzl G, Bolliger CT, Diacon AH, van den Heuvel MM. 2008. Evaluation of adapted whole-blood interferon-gamma release assays for the diagnosis of pleural tuberculosis. Respiration 76:131-138.
9. Converse PJ, et al. 1996. Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. Infect. Immun. 64:4776-4787. (Pubitemid 26357091)
10. Converse PJ, et al. 1998. Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy. Clin. Diagn. Lab. Immunol. 5:871-881. (Pubitemid 28519267)
11. Dannenberg AM, Jr. 2009. Liquefaction and cavity formation in pulmonary TB: a simple method in rabbit skin to test inhibitors. Tuberculosis (Edinb.) 89:243-247.
12. 18F]-2-fluoro- deoxy-Dglucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53:4879-4884.
13. Degirmenci B, et al. 2008. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography. Nucl. Med. Commun. 29:614-622.
14. 18F-FDG PET during acute lung injury. AJR Am. J. Roentgenol. 195:292-300.
15. Doherty M, Wallis RS, Zumla A. 2009. Biomarkers for tuberculosis disease status and diagnosis. Curr. Opin. Pulm. Med. 15:181-187.
16. Eum SY, et al. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137:122-128.
17. Goo JM, et al. 2000. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216:117-121. (Pubitemid 30434730)
18. Gurumurthy P, et al. 2004. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 48:4473-4475. (Pubitemid 39434921)
19. Hamilton CD, et al. 2008. The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. Int. J. Tuberc. Lung Dis. 12:1059-1064.
20. Hancock H, et al. 2009. Evaluation of pulsed high intensity focused ultrasound exposures on metastasis in a murine model. Clin. Exp. Metastasis 26:729-738.
21. 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 124:893-901.
22. Hasan Z, et al. 2009. CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis. PLoS One 4:e8459.
23. Hesseling AC, et al. 2010. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int. J. Tuberc. Lung Dis. 14:560 -570.
24. 18F-FDG PET. Ann. Nucl. Med. 22:533-538.
25. Im JG, et al. 1993. Pulmonary tuberculosis: CT findings-early active disease and sequential change with antituberculous therapy. Radiology 186:653- 660.
26. Jeong YJ, Lee KS. 2008. Pulmonary tuberculosis: up-to-date imaging and management. AJR Am. J. Roentgenol. 191:834-844.
27. Jones HA. 2005. Inflammation imaging. Proc. Am. Thorac. Soc. 2:545-548, 513-514.
28. 18F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology 223:446-451.
29. Kaplan G, Tsenova L. 2011. Pulmonary tuberculosis in the rabbit, p 107-130. In Leong FJ, Dartois V, Dick T (ed), A color atlas of comparative pathology of pulmonary tuberculosis. CRC Press, Boca Raton, FL.
30. 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur. J. Nucl. Med. Mol. Imaging 35:808-814.
31. Kjellsson MC, et al. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56:446-457.
32. Kraft SL, et al. 2004. Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect. Immun. 72:5963-5971. (Pubitemid 39303711)
33. Leong FJ, Eum S, Via LE, and Barry CE, 3rd. 2011. Pulmonary tuberculosis in the human lung, p 107-130. In Leong FJ, Dartois V, Dick T (ed), A color atlas of comparative pathology of pulmonary tuberculosis. CRC Press, Boca Raton, FL.
34. Lurie MB, Abramson S, Heppleston AG. 1952. On the response of genetically resistant and susceptible rabbits to the quantitative inhalation of human type tubercle bacilli and the nature of resistance to tuberculosis. J. Exp. Med. 95:119-134.
35. Manabe YC, et al. 2003. Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect. Immun. 71:6004-6011. (Pubitemid 37205653)
36. Manabe YC, et al. 2008. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb.) 88:187-196.
37. Mitchison DA. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219 -225.
38. Moran-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM. 2010. Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int. J. Tuberc. Lung Dis. 14:1112-1119.
39. 18F-FDG PET in malignant tumors. J. Nucl. Med. 49:1804-1808.
40. Ordway DJ, et al. 2010. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob. Agents Chemother. 54:1820-1833.
41. Padgaonkar KA, et al. 1999. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. Int. J. Tuberc. Lung Dis. 3:627- 631.
42. Panchagnula R, Sancheti P, Rungta S, Agrawal S, Kaul CL. 2003. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol. Pharmacol. Res. 48:383-387. (Pubitemid 36945337)
43. Rosset A, Spadola L, Ratib O. 2004. OsiriX: an open-source software for navigating in multidimensionalDICOMimages. J. Digit. Imaging 17:205-216. (Pubitemid 40378992)
44. Shi C, Shi J, Xu Z. 2011. A review of murine models of latent tuberculosis infection. Scand. J. Infect. Dis. 43:848-856.
45. Skvor J, Trnka L, Kugukovova Z. 1979. Immunoprofile studies in patients with pulmonary tuberculosis. II. Correlation of levels of different classes of immunoglobulins and specific antibodies with the extent of tuberculosis. Scand. J. Respir. Dis. 60:168-171.
46. Tsenova L, Bergtold A, Freedman VH, Young RA, Kaplan G. 1999. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 96:5657-5662. (Pubitemid 29234674)
47. Tsenova L, et al. 2002. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob. Agents Chemother. 46:1887-1895. (Pubitemid 34535212)
48. Tsenova L, Sokol K, Freedman VH, Kaplan G. 1998. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J. Infect. Dis. 177:1563-1572. (Pubitemid 28243580)
49. Vesselle H, et al. 2000. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin. Cancer Res. 6:3837-3844.
50. Via LE, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76:2333-2340.
51. Wahl RL, H Jacene, Y Kasamon and MA Lodge. 2009. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50(Suppl. 1):122S-50S.
52. Wallis RS, et al. 2010. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis. 10:68-69.
53. Weber WW, Hein DW. 1979. Clinical pharmacokinetics of isoniazid. Clin. Pharmacokinet. 4:401-422. (Pubitemid 10210049)
54. Wilkins JJ, et al. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148. (Pubitemid 351758551)